STOCK TITAN

NuCana plc - NCNA STOCK NEWS

Welcome to our dedicated news page for NuCana plc (Ticker: NCNA), a resource for investors and traders seeking the latest updates and insights on NuCana plc.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect NuCana plc's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of NuCana plc's position in the market.

Rhea-AI Summary
NuCana plc (NCNA) has completed the effective change in the ratio of its American Depositary Shares (ADSs) to ordinary shares, with one ADS now representing twenty-five ordinary shares. The change aims to enhance liquidity in the Company's ADSs and comply with Nasdaq's minimum bid price requirement. Shareholders were automatically exchanged their existing ADSs for new ADSs on a one-for-twenty-five basis, with no impact on their proportional equity interest.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-12.36%
Tags
none
-
Rhea-AI Summary
NuCana plc (NASDAQ: NCNA) presented two posters at the AACR Annual Meeting showcasing the effects of NUC-7738 on cancer cell lipid metabolism and ribosome biogenesis. NUC-7738 was found to reprogram lipid metabolism in tumors, making them less aggressive and promoting cancer cell death. The drug alters genes critical for cancer growth and survival, potentially offering a novel approach to inhibit ribosome biogenesis in cancer cells.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.34%
Tags
-
Rhea-AI Summary
NuCana plc (NCNA) plans to change its ADS Ratio from 1:1 to 1:25, aiming to increase liquidity and attract long-term investors.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-15.2%
Tags
none
Rhea-AI Summary
NuCana plc (NCNA) announces encouraging updates on NUC-3373 and NUC-7738, demonstrating promising efficacy and safety. The company's financial results for Q4 2023 show a net loss of £7.7 million. NuCana expects key data readouts for all programs in 2024, with a cash runway into 2025.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-12.92%
Tags
-
Rhea-AI Summary
NuCana plc (NCNA) executives to present at TD Cowen’s 44th Annual Health Care Conference. The event will feature Hugh Griffith, CEO, and Don Munoz, CFO, on March 5, 2024, in Boston, MA. The presentation will be webcast live on the company's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.3%
Tags
conferences
-
Rhea-AI Summary
NuCana plc (NCNA) announced CEO and CFO participation in the Oppenheimer 34th Annual Healthcare Life Sciences Conference. The presentation will be webcast live and available for replay on the company's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.08%
Tags
conferences
Rhea-AI Summary
NuCana plc (NASDAQ: NCNA) announced financial results for the third quarter ended September 30, 2023 and provided updates on its clinical development program with ProTide therapeutics. The company reported promising clinical data for NUC-3373 and NUC-7738, demonstrating favorable safety profiles and encouraging signs of efficacy. NuCana is well-capitalized with an anticipated cash runway into 2025. Key milestones for 2024 include data updates from various clinical studies.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.9%
Tags
-
Rhea-AI Summary
NuCana plc (NASDAQ: NCNA) Receives Approval for Transfer of Listing to Nasdaq Capital Market, Granted Extension to Regain Compliance with Minimum Bid Price Requirement
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary
NuCana plc (Nasdaq: NCNA) to present at Jefferies London Healthcare Conference on November 14, 2023. CEO Hugh Griffith and CFO Don Munoz to host one-on-one meetings. Webcast available for replay on company website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.03%
Tags
conferences
Rhea-AI Summary
NuCana plc (Nasdaq: NCNA) will participate in the Truist Securities 2023 BioPharma Symposium on November 8-9, 2023, in New York, NY. The company's CEO, Hugh Griffith, and CFO, Don Munoz, will host one-on-one meetings at the event.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.13%
Tags
conferences
NuCana plc

Nasdaq:NCNA

NCNA Rankings

NCNA Stock Data

11.84M
29.20M
0.56%
28.43%
0.31%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United Kingdom
3 Lochside Way

About NCNA

nucana is a clinical-stage biopharmaceutical company focused on significantly improving treatment outcomes for patients with cancer by applying our phosphoramidate chemistry technology to transform some of the most widely prescribed chemotherapy agents into more effective and safer medicines. while these conventional agents remain part of the standard of care for the treatment of many solid tumours, their efficacy is limited by cancer cell resistance mechanisms and they are often poorly tolerated. utilising our proprietary protide technology, we are developing new medicines designed to overcome key cancer resistance mechanisms and generate much higher concentrations of anti-cancer metabolites in cancer cells.